Andy Studna, Editor

Dr. Hanne Bak, Senior Vice President of Preclinical Manufacturing and Process Development at Regeneron speaks about her role at the company as well as their work with monoclonal antibodies, the regulatory side of manufacturing, and more.

Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.

John Reites, CEO of THREAD Research, discusses how his organization is adapting to decentralized trials and efforts they're taking to increase patient recruitment.

Dr. Theodore Leng, MD, Medical Advisor to Verana Health and Director of Clinical and Translational Research at the Byers Eye Institute at Stanford, Stanford University Medical School, talks about a recent study he led and presented in early May at the Association for Research in Vision and Ophthalmology Meeting.

New BDO CRO Insights Report reveals high rate of CRA turnover and what organizations are doing to combat it.

Co-conveners of the newly formed Decentralized Trials & Research Alliance, Amir Kalali, MD and Craig Lipset discuss the alliance as well as how COVID-19 has impacted the industry.

Recent webcast addresses what organizations can do to prepare for the next revision of ICH E6.

EVP and General Manager of Hū, April Lewis, discusses why the industry has seen a decline in trial participation and what Hū is doing to combat it.

Sujay Jadhav, global vice president, study start-up, Oracle Health Sciences, spoke with ACT on how study start-up has been impacted by the pandemic and what its future holds beyond COVID.

Jody Casey of Elligo Health Research gives insight into the issue of diversity in trials and what needs to be done to correct it.